BMC cancer, 2023-03, Vol.23 (1), p.295-295, Article 295
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Prognostic value of CYFRA 21 - 1 and Ki67 in advanced NSCLC patients with wild-type EGFR
- Ist Teil von
- BMC cancer, 2023-03, Vol.23 (1), p.295-295, Article 295
- Ort / Verlag
- England: BioMed Central Ltd
- Erscheinungsjahr
- 2023
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- The prognostic value of cytokeratin 19 fragment (CYFRA 21 - 1) and Ki67 in advanced non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) remains to be explored. In this study, 983 primary NSCLC patients from January 2016 to December 2019 were retrospectively reviewed. Finally, 117 advanced NSCLC patients with wild-type EGFR and 37 patients with EGFR mutation were included and prognostic value of CYFRA 21 - 1 and Ki67 were also identified. The patients age, smoking history and the Eastern Corporative Oncology Group (ECOG) performance scores were significantly different between CYFRA21-1 positive and negative groups (p < 0.05), while no significant differences were found in Ki67 high and low groups. The results of over survival (OS) demonstrated that patients with CYFRA21-1 positive had markedly shorter survival time than CYFRA21-1 negative (p < 0.001, For whole cohorts; p = 0.002, For wild-type EGFR). Besides, patients with wild-type EGFR also had shorter survival times than Ki67 high group. Moreover, In CYFRA 21 - 1 positive group, patients with Ki67 high had obviously shorter survival time compared to patients with Ki67 low (median: 24vs23.5 months; p = 0.048). However, Ki67 could not be used as an adverse risk factor for patients with EGFR mutation. Multivariate cox analysis showed that age (HR, 1.031; 95%CI, 1.003 ~ 1.006; p = 0.028), Histopathology (HR, 1.760; 95%CI,1.152 ~ 2.690; p = 0.009), CYFRA 21 - 1 (HR, 2.304; 95%CI,1.224 ~ 4.335; p = 0.01) and Ki67 (HR, 2.130; 95%CI,1.242 ~ 3.652; p = 0.006) served as independent prognostic risk factor for advanced NSCLC patients. Our finding indicated that CYFRA 21 - 1 was an independent prognostic factor for advanced NSCLC patients and Ki67 status could be a risk stratification marker for CYFRA 21 - 1 positive NSCLC patients with wild-type EGFR.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1471-2407eISSN: 1471-2407DOI: 10.1186/s12885-023-10767-9Titel-ID: cdi_doaj_primary_oai_doaj_org_article_5f9962e030934d1a9fcd9bc1fa15bf56
- Format
- –
- Schlagworte
- Analysis, Antigens, Biomarkers, Biomarkers, Tumor - genetics, Carcinoma, Non-Small-Cell Lung - genetics, Care and treatment, CYFRA 21 − 1, Cytokeratin, Diagnosis, Epidermal growth factor, Epidermal growth factor receptors, ErbB Receptors - genetics, Gene mutations, Genetic aspects, Health aspects, Hospitals, Humans, Keratin-19 - genetics, Ki-67 antigen, Ki67, Kinases, Laboratories, Lung cancer, Lung cancer, Non-small cell, Lung diseases, Lung Neoplasms - genetics, Medical prognosis, Mutation, Non-small cell lung carcinoma, NSCLC, Pathology, Patients, Prognosis, Retrospective Studies, Risk factors, Small cell lung carcinoma, Testing, Tumors, Wild-type EGFR